Loading...
Assessing brain amyloid β42 (Aβ42; “bad” amyloid) has required either positron emission tomography (PET) scans or assays of cerebrospinal fluid. To identify a plasma measure that predicts brain Aβ42, researchers previously used immunoprecipitation–mass spectroscopy to develop a composite plasma measure consisting of the ratios of amyloid precursor protein to Aβ40 and of Aβ40 to Aβ42. In the current study, the composite measure was compared with PET–Pittsburgh compound B (PiB) and other amyloid ligands as the “standard of truth,” in a discovery sample from Japan (N=121) and a validation sample from Australia (N=252).
The two groups had a mean age of 74 and had similar numbers of people with dementia of the Alzheimer type (DAT), mild cognitive…